GPX4 and cancer: Featuring with high mesenchymal phenotypes, cancer cells of melanoma, prostate cancer and sarcomas, which are respectively resistant to the original cancer therapy, show upregulated susceptibility to GPX4-targeted ferroptosis (Hangauer et al., 2017; Viswanathan et al., 2017).